What is it about?
Mild cognitive impairment (MCI) associated with physical frailty gave rise to the new concept of cognitive frailty (CF). MCI and CF have close relationship with dementia from Alzheimer's disease and to diagnosis them as early as possible is important, in order to start interventions to delay or even revert both conditions. Biomarkers can be important to this diagnosis and blood ADAM10 was proven to be a good candidate to identify older adults with MCI.
Featured Image
Photo by Rod Long on Unsplash
Why is it important?
Together with other clinical criteria, ADAM10 could be a relevant, low-invasive, low-cost and fast processing biomarker tool to help in the early and accurate diagnosis of MCI, despite not suitable to identify CF.
Read the Original
This page is a summary of: ADAM10 as a biomarker of mild cognitive impairment but not of cognitive frailty, Experimental Gerontology, March 2021, Elsevier,
DOI: 10.1016/j.exger.2021.111303.
You can read the full text:
Contributors
The following have contributed to this page
